| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
145,981,000 |
| Market
Cap: |
294.88(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.13 - $2.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
25,516 |
25,516 |
25,516 |
| Total Sell Value |
$0 |
$30,379 |
$30,379 |
$30,379 |
| Total People Sold |
0 |
3 |
3 |
3 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Parshall B Lynne |
Director |
– • • |
2014-08-14 |
4 |
AS |
$7.04 |
$12,324 |
D/D |
(1,750) |
6,993,850 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-13 |
4 |
AS |
$7.02 |
$15,788 |
D/D |
(2,250) |
6,096,600 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-08-13 |
4 |
AS |
$7.02 |
$15,788 |
D/D |
(2,250) |
6,995,600 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-08-08 |
4 |
AS |
$6.80 |
$12,583 |
D/D |
(1,850) |
6,997,850 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-08 |
4 |
AS |
$6.80 |
$12,583 |
D/D |
(1,850) |
6,098,850 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-08-07 |
4 |
AS |
$6.66 |
$17,322 |
D/D |
(2,600) |
6,999,700 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-07 |
4 |
AS |
$6.66 |
$17,322 |
D/D |
(2,600) |
6,100,700 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-08-06 |
4 |
AS |
$7.08 |
$22,300 |
D/D |
(3,150) |
7,002,300 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-06 |
4 |
AS |
$7.08 |
$22,300 |
D/D |
(3,150) |
6,103,300 |
|
- |
|
| Xanthopoulos Kleanthis G |
President & CEO |
• • – |
2014-08-05 |
4 |
AS |
$7.06 |
$24,739 |
D/D |
(3,505) |
0 |
|
- |
|
| Xanthopoulos Kleanthis G |
President & CEO |
• • – |
2014-08-05 |
4 |
OE |
$0.38 |
$1,332 |
D/D |
3,505 |
3,505 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-08-01 |
4 |
AS |
$6.21 |
$16,153 |
D/D |
(2,600) |
6,106,450 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-08-01 |
4 |
AS |
$6.21 |
$16,153 |
D/D |
(2,600) |
7,005,450 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-07-31 |
4 |
AS |
$6.42 |
$11,235 |
D/D |
(1,750) |
6,109,050 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-07-31 |
4 |
AS |
$6.42 |
$11,235 |
D/D |
(1,750) |
7,008,050 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-07-30 |
4 |
AS |
$6.60 |
$6,602 |
D/D |
(1,000) |
6,110,800 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-07-30 |
4 |
AS |
$6.60 |
$6,602 |
D/D |
(1,000) |
7,009,800 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-07-25 |
4 |
AS |
$6.55 |
$11,137 |
D/D |
(1,700) |
7,010,800 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-07-25 |
4 |
AS |
$6.55 |
$11,137 |
D/D |
(1,700) |
6,111,800 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-07-24 |
4 |
AS |
$6.81 |
$12,598 |
D/D |
(1,850) |
7,012,500 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-07-24 |
4 |
AS |
$6.81 |
$12,598 |
D/D |
(1,850) |
6,113,500 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-07-23 |
4 |
AS |
$6.88 |
$11,702 |
D/D |
(1,700) |
7,014,350 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-07-23 |
4 |
AS |
$6.88 |
$11,702 |
D/D |
(1,700) |
6,115,350 |
|
- |
|
| Parshall B Lynne |
Director |
– • • |
2014-07-18 |
4 |
AS |
$6.80 |
$34,001 |
D/D |
(5,000) |
7,016,050 |
|
- |
|
| Alnylam Pharmaceuticals, Inc. |
10% Owner |
– – • |
2014-07-18 |
4 |
AS |
$6.80 |
$34,001 |
D/D |
(5,000) |
6,117,050 |
|
- |
|
341 Records found
|
|
Page 11 of 14 |
|
|
0.10 (5.21%) 
